Page last updated: 2024-11-12

mugineic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mugineic acid: RN refers to (2S-(1(alphaR*(R*),betaR*),2R*))-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mugineic acid : An azetidinecarboxylic acid that is the parent of the class of mugineic acids. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11067153
CHEBI ID25426
SCHEMBL ID1062827
MeSH IDM0149921

Synonyms (14)

Synonym
mugineic acid
n-(3-(3-carboxypropylamino)-2-hydroxy-3-carboxypropyl)azetidine-2-carboxylic acid
CHEBI:25426
69199-37-7
4-[(2s)-2-carboxyazetidin-1-yl]-n-[(3s)-3-carboxy-3-hydroxypropyl]-l-allothreonine
1-azetidinebutanoic acid, 2-carboxyl-alpha-((3-carboxy-3-hydroxypropyl)amino)-beta-hydroxy-, (2s-(1(alphar*(r*),betar*),2r*))-
kr256jy76i ,
unii-kr256jy76i
SCHEMBL1062827
mugineic acid, (-)-
1-azetidinebutanoic acid, 2-carboxy-.alpha.-(((3s)-3-carboxy-3-hydroxypropyl)amino)-.beta.-hydroxy-, (.alpha.s,.beta.s,2s)-
(.alpha.s,.beta.s,2s)-2-carboxy-.alpha.-(((3s)-3-carboxy-3-hydroxypropyl)amino)-.beta.-hydroxy-1-azetidinebutanoic acid
Q27109879
(2s)-1-[(2s,3s)-3-carboxy-3-[[(3s)-3-carboxy-3-hydroxypropyl]amino]-2-hydroxypropyl]azetidine-2-carboxylic acid

Research Excerpts

Overview

Deoxymugineic acid (DMA) is a natural metal chelator produced by graminaceous plants.

ExcerptReferenceRelevance
"Deoxymugineic acid (DMA) is a member of the mugineic acid family phytosiderophores (MAs), which are natural metal chelators produced by graminaceous plants. "( Deoxymugineic acid increases Zn translocation in Zn-deficient rice plants.
Inoue, H; Matsuhashi, S; Mori, S; Nakanishi, H; Nishizawa, NK; Suzuki, M; Takahashi, M; Tsukamoto, T; Watanabe, S, 2008
)
1.37

Bioavailability

ExcerptReferenceRelevance
" As these phytosiderophores have the ability to form thermodynamically stable complexes with other metal cations present in the growing medium, they have also been implicated in the transport and bioavailability of these metals in the environment."( Anion exchange liquid chromatography--inductively coupled plasma-mass spectrometry detection of the Co2+, Cu2+, Fe3+ and Ni2+ complexes of mugineic and deoxymugineic acid.
Bakkaus, E; Collins, RN; Gouget, B; Morel, JL, 2006
)
0.53
"Iron (Fe) is an essential nutrient, but is poorly bioavailable because of its low solubility in alkaline soils; this leads to reduced agricultural productivity."( Development of a mugineic acid family phytosiderophore analog as an iron fertilizer.
Aung, MS; Chiba, Y; Fujino, H; Fukushima, K; Kanaki, M; Kobayashi, K; Kobayashi, T; Masuda, H; Mera, A; Mukaiyama, H; Murata, Y; Nakanishi, H; Nakayama, A; Namba, K; Nishio, S; Nishizawa, NK; Sasaki, S; Shrestha, BB; Suzuki, M; Takeuchi, M; Tanino, K; Tsugawa, R; Urabe, A; Watanabe, T, 2021
)
0.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
mugineic acids
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (4.55)18.7374
1990's4 (9.09)18.2507
2000's20 (45.45)29.6817
2010's14 (31.82)24.3611
2020's4 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.05 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (15.91%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other37 (84.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]